Fresenius and WuXi Biologics Enter Biosimilar Development Agreement
The exclusive agreement gives Fresenius access to up to 37 identified biosimilar candidates over the next decade.
BAD HOMBURG VOR DER HOEHE (dpa-AFX) - Fresenius SE & Co. KGaA has entered an exclusive development agreement with WuXi Biologics (2269.HK), which provides Fresenius access to up to 37 identified biosimilar candidates over the next decade. The company said the agreement provides access to a scalable…